CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it moves forward with its COVID-19 mRNA vaccine. Deputy CEO Franz-Werner Haas took over as CEO in March, just five days after Ingmar Hoerr replaced Daniel Menichella as CEO. Also last month, CureVac received an €80 million ($88.0 million) EIB loan to expand its COVID-19 manufacturing capacity (see "CureVac CEO Hoerr Takes

Read the full 862 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers